I-HUMAN ADVANCED DDX CASE STUDY: MARGARET
WILSON (60-YEAR OLD FEMALE WITH SHORTNESS OF
BREATH) | COMPLETE VIRTUAL PATIENT ASSESSMENT,
FULL HPI, PAST MEDICAL HISTORY (PMH), FAMILY &
SOCIAL HISTORY, REVIEW OF SYSTEMS (ROS),WITH
COMPLETE SOLUTIONS EXAM with Questions and
Answers/Plus a Rationale Updated 2026 A+/Instant
Download PDF
EXAM COVERAGE
1. Advanced Differential Diagnosis for Progressive Dyspnea
2. Evaluation of Heart Failure with Reduced Ejection Fraction (HFrEF)
3. Pathophysiological Assessment of Volume Overload States
4. Clinical Correlation of Physical Exam Findings (S3, JVD, Crackles)
5. Interpretation of Cardiovascular Biomarkers and Imaging
6. Evidence-Based Guideline-Directed Medical Therapy (GDMT)
7. Management of Comorbidities and Risk Factors in Elderly Patients
8. Pharmacological Stabilization and Titration Strategies
9. Prevention of Acute Decompensated Heart Failure (ADHF)
10. Long-term Prognostic Monitoring and Patient Education
1. A 60-year-old female presents with progressive exertional dyspnea and orthopnea. Clinical
assessment reveals JVD to 14 cm, S3 gallop, and diffuse crackles. An echocardiogram shows an
, EF of 30%. Given the patient's acute decompensated state, which diagnostic test is most essential
to evaluate for concurrent coronary artery disease as an etiology for her HFrEF?
A. Myocardial perfusion imaging (stress test)
B. Coronary angiography
C. Cardiac MRI with gadolinium
D. Coronary artery calcium scoring
Answer: B
CORRECT ANSWER : B
Rationale: In a patient with new-onset or newly decompensated HFrEF, coronary angiography
is the gold standard to definitively identify or rule out obstructive coronary artery disease as a
primary etiology. Stress testing (A) is contraindicated in acute decompensation, and calcium
scoring (D) does not confirm flow-limiting stenosis.
2. A patient with HFrEF (EF 30%) is currently managed on lisinopril 20mg daily and metoprolol
succinate 50mg daily. She reports no improvement in dyspnea. What is the most appropriate next
step in her Guideline-Directed Medical Therapy (GDMT)?
A. Increase lisinopril to 40mg
B. Transition lisinopril to Sacubitril/Valsartan
C. Add amlodipine for blood pressure control
D. Discontinue metoprolol and initiate digoxin
Answer: B
CORRECT ANSWER : B
Rationale: Current heart failure guidelines recommend ARNI (Sacubitril/Valsartan) as the
preferred therapy over ACE inhibitors for mortality reduction in HFrEF. Transitioning from an
ACE inhibitor provides superior neurohormonal blockade. Amlodipine (C) is not a mortality-
reducing agent in HFrEF, and digoxin (D) is not a first-line therapy.
3. During an I-Human encounter, you elicit a positive hepatojugular reflux (HJR). What is the
physiological significance of this physical exam finding?
A. It indicates acute liver failure
, B. It confirms elevated central venous pressure and systemic venous congestion
C. It suggests primary pulmonary hypertension
D. It is a sign of aortic valve disease
Answer: B
CORRECT ANSWER : B
Rationale: A positive HJR is a specific indicator of systemic venous congestion, often seen in
right-sided heart failure or biventricular failure where the heart cannot accommodate increased
venous return. It is not associated with liver failure (A) or aortic valve disease (D).
4. The patient’s NT-proBNP is 8,000 pg/mL. Which mechanism is primarily responsible for the
elevation of this biomarker?
A. Peripheral ischemia
B. Myocardial stretch due to volume and pressure overload
C. Excessive dietary sodium intake
D. Chronic inflammation of the cardiac valves
Answer: B
CORRECT ANSWER : B
Rationale: NT-proBNP is released by cardiomyocytes in response to ventricular wall stress and
stretch. While volume overload (C) causes the stretch, the biomarker elevation itself is a direct
product of the myocardial response to that mechanical stress.
5. A 60-year-old female with HFrEF is prescribed spironolactone. Why must you monitor her
serum potassium levels within 1-2 weeks of initiation?
A. To prevent drug-induced arrhythmia
B. To monitor for life-threatening hyperkalemia due to MRA-mediated potassium
retention
C. To assess for renal perfusion improvement
D. To titrate the diuretic effect
Answer: B
, CORRECT ANSWER : B
Rationale: Spironolactone is a mineralocorticoid receptor antagonist (MRA) that inhibits
potassium excretion in the distal tubule. Given the patient likely takes an ACE inhibitor or ARNI,
the risk of hyperkalemia is significant and must be screened early to prevent cardiac conduction
abnormalities.
6. You are reviewing the patient's medication list. She is currently taking ibuprofen for chronic
knee pain. What is your clinical recommendation?
A. Continue ibuprofen as it does not interfere with heart failure medication
B. Discontinue ibuprofen and transition to acetaminophen, as NSAIDs promote fluid
retention and reduce diuretic efficacy
C. Reduce the ibuprofen dose by half to maintain safety
D. Add a second diuretic to counteract the effect of the ibuprofen
Answer: B
CORRECT ANSWER : B
Rationale: NSAIDs inhibit cyclooxygenase, leading to reduced prostaglandin-mediated renal
vasodilation. This leads to sodium and water retention and can cause acute kidney injury,
directly counteracting the goals of GDMT and diuretic therapy in HFrEF.
7. The patient’s HPI reveals a history of paroxysmal nocturnal dyspnea (PND). Which mechanism
best explains the timing of this symptom?
A. Increased nocturnal respiratory drive
B. Redistribution of peripheral fluid into the intravascular space while recumbent,
increasing pulmonary venous pressure
C. Nocturnal bronchospasm triggered by temperature changes
D. Physiological decrease in heart rate during sleep
Answer: B
CORRECT ANSWER : B
Rationale: When a patient with HFrEF lies flat, edema from the lower extremities is mobilized
back into the circulation. In a failing heart, this increases the left ventricular end-diastolic
pressure, leading to pulmonary congestion and the sensation of suffocation.
WILSON (60-YEAR OLD FEMALE WITH SHORTNESS OF
BREATH) | COMPLETE VIRTUAL PATIENT ASSESSMENT,
FULL HPI, PAST MEDICAL HISTORY (PMH), FAMILY &
SOCIAL HISTORY, REVIEW OF SYSTEMS (ROS),WITH
COMPLETE SOLUTIONS EXAM with Questions and
Answers/Plus a Rationale Updated 2026 A+/Instant
Download PDF
EXAM COVERAGE
1. Advanced Differential Diagnosis for Progressive Dyspnea
2. Evaluation of Heart Failure with Reduced Ejection Fraction (HFrEF)
3. Pathophysiological Assessment of Volume Overload States
4. Clinical Correlation of Physical Exam Findings (S3, JVD, Crackles)
5. Interpretation of Cardiovascular Biomarkers and Imaging
6. Evidence-Based Guideline-Directed Medical Therapy (GDMT)
7. Management of Comorbidities and Risk Factors in Elderly Patients
8. Pharmacological Stabilization and Titration Strategies
9. Prevention of Acute Decompensated Heart Failure (ADHF)
10. Long-term Prognostic Monitoring and Patient Education
1. A 60-year-old female presents with progressive exertional dyspnea and orthopnea. Clinical
assessment reveals JVD to 14 cm, S3 gallop, and diffuse crackles. An echocardiogram shows an
, EF of 30%. Given the patient's acute decompensated state, which diagnostic test is most essential
to evaluate for concurrent coronary artery disease as an etiology for her HFrEF?
A. Myocardial perfusion imaging (stress test)
B. Coronary angiography
C. Cardiac MRI with gadolinium
D. Coronary artery calcium scoring
Answer: B
CORRECT ANSWER : B
Rationale: In a patient with new-onset or newly decompensated HFrEF, coronary angiography
is the gold standard to definitively identify or rule out obstructive coronary artery disease as a
primary etiology. Stress testing (A) is contraindicated in acute decompensation, and calcium
scoring (D) does not confirm flow-limiting stenosis.
2. A patient with HFrEF (EF 30%) is currently managed on lisinopril 20mg daily and metoprolol
succinate 50mg daily. She reports no improvement in dyspnea. What is the most appropriate next
step in her Guideline-Directed Medical Therapy (GDMT)?
A. Increase lisinopril to 40mg
B. Transition lisinopril to Sacubitril/Valsartan
C. Add amlodipine for blood pressure control
D. Discontinue metoprolol and initiate digoxin
Answer: B
CORRECT ANSWER : B
Rationale: Current heart failure guidelines recommend ARNI (Sacubitril/Valsartan) as the
preferred therapy over ACE inhibitors for mortality reduction in HFrEF. Transitioning from an
ACE inhibitor provides superior neurohormonal blockade. Amlodipine (C) is not a mortality-
reducing agent in HFrEF, and digoxin (D) is not a first-line therapy.
3. During an I-Human encounter, you elicit a positive hepatojugular reflux (HJR). What is the
physiological significance of this physical exam finding?
A. It indicates acute liver failure
, B. It confirms elevated central venous pressure and systemic venous congestion
C. It suggests primary pulmonary hypertension
D. It is a sign of aortic valve disease
Answer: B
CORRECT ANSWER : B
Rationale: A positive HJR is a specific indicator of systemic venous congestion, often seen in
right-sided heart failure or biventricular failure where the heart cannot accommodate increased
venous return. It is not associated with liver failure (A) or aortic valve disease (D).
4. The patient’s NT-proBNP is 8,000 pg/mL. Which mechanism is primarily responsible for the
elevation of this biomarker?
A. Peripheral ischemia
B. Myocardial stretch due to volume and pressure overload
C. Excessive dietary sodium intake
D. Chronic inflammation of the cardiac valves
Answer: B
CORRECT ANSWER : B
Rationale: NT-proBNP is released by cardiomyocytes in response to ventricular wall stress and
stretch. While volume overload (C) causes the stretch, the biomarker elevation itself is a direct
product of the myocardial response to that mechanical stress.
5. A 60-year-old female with HFrEF is prescribed spironolactone. Why must you monitor her
serum potassium levels within 1-2 weeks of initiation?
A. To prevent drug-induced arrhythmia
B. To monitor for life-threatening hyperkalemia due to MRA-mediated potassium
retention
C. To assess for renal perfusion improvement
D. To titrate the diuretic effect
Answer: B
, CORRECT ANSWER : B
Rationale: Spironolactone is a mineralocorticoid receptor antagonist (MRA) that inhibits
potassium excretion in the distal tubule. Given the patient likely takes an ACE inhibitor or ARNI,
the risk of hyperkalemia is significant and must be screened early to prevent cardiac conduction
abnormalities.
6. You are reviewing the patient's medication list. She is currently taking ibuprofen for chronic
knee pain. What is your clinical recommendation?
A. Continue ibuprofen as it does not interfere with heart failure medication
B. Discontinue ibuprofen and transition to acetaminophen, as NSAIDs promote fluid
retention and reduce diuretic efficacy
C. Reduce the ibuprofen dose by half to maintain safety
D. Add a second diuretic to counteract the effect of the ibuprofen
Answer: B
CORRECT ANSWER : B
Rationale: NSAIDs inhibit cyclooxygenase, leading to reduced prostaglandin-mediated renal
vasodilation. This leads to sodium and water retention and can cause acute kidney injury,
directly counteracting the goals of GDMT and diuretic therapy in HFrEF.
7. The patient’s HPI reveals a history of paroxysmal nocturnal dyspnea (PND). Which mechanism
best explains the timing of this symptom?
A. Increased nocturnal respiratory drive
B. Redistribution of peripheral fluid into the intravascular space while recumbent,
increasing pulmonary venous pressure
C. Nocturnal bronchospasm triggered by temperature changes
D. Physiological decrease in heart rate during sleep
Answer: B
CORRECT ANSWER : B
Rationale: When a patient with HFrEF lies flat, edema from the lower extremities is mobilized
back into the circulation. In a failing heart, this increases the left ventricular end-diastolic
pressure, leading to pulmonary congestion and the sensation of suffocation.
